.svg)
The science of today.The medicine of tomorrow.
.avif)
.avif)
Developing a medicine takes a village.
Brilliant science takes focus, diligence, creativity, and a great idea. What comes next draws on many more hands than any one lab holds.
Translating science into medicine demands a scale that research labs can’t provide. We take only science we believe is exceptional, and when we do, your work joins an ecosystem built to take it to patients fast.
We develop protein-based medicines, well and fast.
We take a molecule with in-vivo/ex-vivo proof of concept, and drive it rapidly to clinical proof of concept.
.avif)
.avif)
.avif)
.avif)
A package ready for the clinic, ready to become a medicine
Reinforcement learning happens at an operational level, with outcomes and data feeding back into one system. Every program's results inform the next augmenting the scale of the engine to compound translational work across programs.
Our 500 m² BSL-2 facility closes the loop between design and data, allowing a fast iteration of protein production, and functional assays with cell-lines and primary tissue. Cycle after cycle, from developability into IND-enabling work.
We derive the optimal first patient population and predict biomarkers based on our proprietary mechanistic models, to guide protein design and improve the success probability of the first clinical proof.
population mechanistically
Our own generative tools, alongside open frameworks like BoltzGen, rank thousands of de novo binders against those specs. Affinity, valency and linker geometry get optimised in weeks.
As we optimize the molecule for the clinic, our quantitative systems-pharmacology twins simulate it against a virtual model of the target organ and disease to define specs (like the affinity ratios a multi-specific needs) up front.
.avif)
Our biologics-focused pipeline moves rapidly in the indications that need it.
We only in-license multifunctional biologics. Bispecifics, engagers, degraders, enzyme-linked proteins against high unmet need.
Programs that we’ve brought into our engine include:
.svg){kind=icon}
.svg){kind=icon}
.avif)
Alexander Belcredi is a biotech entrepreneur and angel investor with over 15 years in pharma. In 2017 he co-founded PhagoMed, developing phage-based therapies for drug-resistant infections, and led the company as Co-CEO from founding through its acquisition by BioNTech in 2021. He then co-led BioNTech's R&D hub in Austria, advancing antibacterial programs at the intersection of microbiology, generative AI and mRNA technology. Alexander is now Co-Founder & CEO of Sameric Bio, translating promising academic biology into clinical proof-of-concept. He also mentors scientists and founders via Creative Destruction Lab, invests through LANA Ventures, and holds an MA from St Andrews and an MBA from INSEAD after nine years at BCG.
.svg)
.avif)
.avif)
Lorenzo Corsini is a biotech entrepreneur and structural biologist with a PhD in molecular and structural biology from EMBL Heidelberg. In 2017, he co-founded PhagoMed, developing phage- and lysin-based therapies for drug-resistant infections; he built the company's foundational patent estate and originated the RiboLysin concept - combining engineered lysins with mRNA delivery - that became a core BioNTech discovery platform. He led PhagoMed through its acquisition by BioNTech in 2021, then became Managing Director of BioNTech's R&D hub in Austria, overseeing its antibacterial pipeline and platform development. Lorenzo is now Co-Founder & CEO of Sameric Bio, alongside board roles at Equatic, Vienna BioCenter, and LANA Ventures. He spent nine years as a Partner at Boston Consulting Group.
.png)
Adriana Badarau is a drug discovery scientist with more than 15 years turning biology into medicines. At Arsanis Biosciences, she led antibody discovery and protein analytics, advancing four programs to preclinical development, two of which reached Phase 2 trials. At X4 Pharmaceuticals, she led discovery of genotype-phenotype correlations that enabled the approval of Mavorixafor (XOLREMDI). She then joined BioNTech's R&D hub in Austria as Senior Director Discovery, where she led the RiboLysin platform - fusing AI-guided and rational protein engineering with wet-lab and mRNA-delivery validation to turn engineered lysins into a new antibacterial modality - building the in-silico LysinBuilder engine and leading a team of 20 scientists from early discovery through preclinical stage. Adriana is now Co-Founder & CSO of Sameric Bio, holding a PhD in Chemistry and Biochemistry from the University of Huddersfield.
.png)
Albina Poljak is a biotech operator specializing in program management and business development. At AFFiRiS AG, she rose from staff scientist to Head of Business Development, leading vaccine programs and new business opportunities. She joined PhagoMed as Director of Business Development, where she led licensing and partnering all the way to PhagoMed’s successful exit to BioNTech. At BioNTech, she served in a global role as Senior Director R&D Program Management, directing BNT331 - BioNTech's recombinant antibacterial lysin - all the way from bench to Phase 2a, alongside other high-profile programs she led through IND and into clinical trials, including collaborations with top-10 global pharmaceutical companies. Albina is now Co-Founder & CPO of Sameric Bio, holding a PhD from the University of Vienna and Valneva and postgraduate training in project management from the University of Salzburg Business School.
License with us, and get the village.
Our founders built and ran the BioNTech R&D site in Austria. They've carried molecules to patients and run biologics development at massive scale.
Around them we've assembled what a first-time team can't: in-house AI-native protein engineers, biomathematicians and translational scientists, plus advisors and investors from top-10 pharma, practising physicians and fellow founders.
.avif)
.svg)
.svg)
.svg)
.avif)
.avif)
How we partner
We advise originators before any deal, license as their preferred partner, and structure each program so the inventor shares in the specific asset they created.
.svg)
Bring us your science. We’ll bring it to the world.
.svg)
Contact
contact@sameric.bioFollow
LinkedInAddress
Helmut Qualtinger Gasse 2
1030 Vienna, Austria
